House
Sign inCreate account
Drug lookup
Drug reference

olaparib

PARP inhibitor · null

PARP inhibitornullATC null
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
X
FDA category + note
Top interactionssee all 12 →
  • AdalimumabSevereDatabaseDDInter
  • AmprenavirSevereDatabaseDDInter
  • ApalutamideSevereDatabaseDDInter
  • AprepitantSevereDatabaseDDInter

Mechanism

Olaparib inhibits poly(ADP-ribose) polymerase (PARP) in cancers with BRCA mutations.

Indications

breast cancer (BRCA mutation)ovarian cancer (BRCA mutation)pancreatic cancer (BRCA mutation)prostate cancer (BRCA mutation)BRCA-mutated ovarian cancer (monotherapy after three or more prior lines of chemotherapy; after first-line platinum-based chemotherapy)HER2-negative metastatic breast cancer (after chemotherapy or appropriate endocrine therapy for hormone receptor–positive tumors)metastatic pancreatic adenocarcinoma (after platinum-based chemotherapy)metastatic castration-resistant prostate cancer (after endocrine therapy with enzalutamide or abiraterone)Oral agent used as an adjunct to chemotherapy for women with high-risk, germline BRCA-mutated, HER2-negative breast cancer who have completed (neo)adjuvant chemotherapyFor a year, in women with HER2-negative germline BRCA-mutated breast cancer who have received (neo)adjuvant chemotherapy

Pharmacokinetics

Half-life
14.9 h (elimination)
Bioavailability
rapidly absorbed (oral)
Metabolism
CYP3A4 (primarily)

Side effects

Common
nauseavomitingloss of appetitefatiguemuscle and joint painlow blood cell countsanemia
Serious
  • MDS and AML (approximately 1.5% of patients, mostly fatal)
  • pneumonitis (0.8%, with some risk of fatal outcome)
  • venous thromboembolic events (including pulmonary embolism)

Pregnancy & lactation

Pregnancy

X

Drug interactions

Adalimumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Amprenavir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Apalutamide
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Aprepitant
Severe
Database

Increased drug exposure.

Drug exposure is increased or reduced when administered in combination with a CYP3A4 inhibitor or inducer, respectively.

Source: DDInter

Armodafinil
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Atazanavir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Baricitinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Berotralstat
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Boceprevir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Bosentan
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Carbamazepine
Severe
Database

Reduced drug exposure.

Drug exposure is increased or reduced when administered in combination with a CYP3A4 inhibitor or inducer, respectively.

Source: DDInter

Cenobamate
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Related guidelines

Breast cancer
ICMR · Oncology · 2022
Breast cancer
ESMO · Oncology · 2024
Initial monotherapy for newly diagnosed epilepsy
ILAE · Neurology · 2013
Cervical cancer screening and management
ICMR · Oncology · 2022
Tobacco-related cancer prevention
ICMR · Oncology · 2021

Other PARP inhibitor drugs

talazoparib
0 brands

Ask House about olaparib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team